Search For

Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma

Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways

Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma

Lymphatic spread from left-sided intrahepatic cholangiocarcinoma: reconsiderations based on the lymphatic drainage from the liver

Chinese expert consensus on composite ablation system for the treatment of primary liver cancer (2023 edition)

Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease

Progression of liver disease and associated risk of hepatocellular carcinoma

Reflections and perspectives on adjuvant treatment in the setting of resected hepatocellular carcinoma

Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma

The role of percutaneous hepatic perfusion (PHP) in the treatment of cholangiocarcinoma

Role of temporary portosystemic surgical shunt during liver resection to prevent a post-resection small for size-like syndrome

Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition)